Answers are grounded in this paper and cite their sources.
Objective: Acute kidney injury (AKI) is a frequent and serious complication in infants after cardiac surgery. Glutamine (GLN), a conditionally essential amino acid, has demonstrated renoprotective potential in animal models and has been shown to attenuate biomarkers of kidney damage in high-risk patients undergoing cardiac surgery. However, whether these renoprotective benefits extend to pediatric patients remains unknown. Methods: We conducted a single-center, randomized, double-blind, placebo-controlled trial in infants and young children younger than 3 years undergoing cardiac surgery with cardiopulmonary bypass. Ninety-four patients were randomly assigned to receive intravenous alanyl-glutamine (0.4 g/kg/day, n = 47) or 0.9% saline placebo (n = 47), administered from anesthesia induction and continued for 4 consecutive days (the day of surgery and the first 3 postoperative days). The primary outcome was the incidence of AKI within 72 h postoperatively, defined according to the KDIGO criteria. Secondary outcomes included the requirement for peritoneal dialysis (PD), diuretic use, serum creatinine (Scr), neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, procalcitonin, and the lengths of ICU and hospital stay. Results: The incidence of KDIGO-defined AKI was lower in the GLN group than in the control group (14.9% vs. 40.4%; p = 0.010). Among the prespecified secondary outcomes, the requirement for PD (0% vs. 12.8%; p = 0.026) and diuretic use (6.4% vs. 23.4%; p = 0.040) were also lower in the GLN group. Postoperative NGAL concentrations were lower in the GLN group at 24, 48, and 72 h (p < 0.050 for each time point). No significant differences were observed in the lengths of ICU or hospital stay. Conclusions: In this single-center trial, perioperative GLN supplementation was associated with a lower incidence of postoperative AKI, a lower requirement for PD, and less diuretic use in infants undergoing elective cardiac surgery. These exploratory findings support a possible renoprotective role for GLN in this high-risk population but require confirmation in larger multicenter trials before adoption into clinical practice.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: